Favipiravir
Cross-source consensus on Favipiravir from 1 sources and 4 claims.
1 sources · 4 claims
How it works
Dosage & preparation
Background
Evidence quality
Highlighted claims
- In SAFARI, favipiravir was administered orally using a high-dose regimen of 6,000 mg on day 1 followed by 1,200 mg twice daily on days 2-10. — Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial
- Favipiravir is a pyrazinecarboxamide antiviral originally developed and registered for influenza. — Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial
- Favipiravir inhibits RNA polymerase across multiple negative-strand RNA viruses. — Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial
- Before SAFARI, no randomized trial had systematically evaluated favipiravir in humans with Lassa fever. — Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial